KRAS G12D mutation protein (KRAS(G12D))

KRAS G12D is a mutated form of the Kirsten rat sarcoma viral oncogene homolog protein, which acts as a GTPase. It is one of the most common mutations associated with cancer, particularly pancreatic cancer. The mutation impairs GTP hydrolysis, leading to continuous activation of signal transduction pathways, such as the MAPK pathway, promoting cell proliferation and tumorigenesis. Recent developments include specific inhibitors targeting the G12D mutation to block its oncogenic activities. Note: The term "neoantigen" typically refers to mutated peptides presented by MHC molecules on cancer cells, making them potential targets for immunotherapies. However, in this context, "KRAS G12D neoantigen" refers to the mutated protein itself, which is a therapeutic target due to its role in cancer.

Other names

KRAS G12DOncogenic KRAS(G12D)

Inhibition of KRAS(G12D) signaling, Protein degradation